

## List of Tables

Table No.	Table Captions	Page No.
2.1	Top ten countries for number of adult population (aged 20–79 years) with diabetes in 2013 and 2035	10
2.2	PT structure and formula	39
2.3	PT content in certain natural foods	40
4.1	Drugs, chemicals and antibodies	53
4.2	List of equipments and software	55
4.3	Composition of streptozotocin buffer (for 50 ml)	64
4.4	Perfusion Buffer Composition	69
4.5	Myocyte digestion buffer composition	69
4.6	Myocyte stopping buffer composition	70
4.7	Myocyte Planting medium (50 ml)	70
4.8	Myocyte culture medium (50 ml)	70
4.9	Composition of 1X lysis buffer	75
4.10	Standard dilution of BSA	76
4.11	Preparation of PCR mixture	88
4.12	List of primer sequence	88
4.13	Preparation of 1.0 mm gel (for 2 gels)	91
4.14	Preparation of 1.5 mm gel (for 2 gels)	91
4.15	Preparation of SDS-PAGE Running buffer (10x) (1 L, pH 8.3)	91
4.16	Preparation of Transfer buffer (10x) (1 L, pH 8.3)	92
4.17	Preparation of Blocking buffer (20 ml)	92
4.18	Preparation of Washing buffer (1 L)	92
5.1	Effect of PT treatment on body weight and weight gain of experimental rats	93
5.2	Effect of PT on FBG levels of experimental rats	94
5.3	Effect of PT treatment on insulin sensitivity parameters of experimental rats	96
5.4	Hepatic TBARS, SOD and GSH levels in experimental rats after eight weeks	102
5.5	Effect of PT treatment on the MAP, heart rate, body weight and hypertrophy index in the control and fructose-fed diabetic rats	104
5.6	Effect of PT treatment on blood glucose, serum levels of LDH, CK-MB and AST in control and fructose-fed diabetic rats	105
5.7	Effect of PT treatment on general characteristics of experimental rats	117